Ticker
EU secures deal with Novavax for potential Covid-19 vaccine
By EUobserver
The European Commission announced on Wednesday that it had signed a preliminary deal for the purchase of 200 million doses of the promising Covid-19 vaccine developed by the US pharmaceutical company Novavax. The doses will be delivered between the end of 2021 and 2023, but the vaccine still needs to be approved by the European Medicine Agency. Nearly 60 percent of the adult population in the EU is fully-vaccinated.